(S)-2-(4’-Bromo-[1,1’-Biphenyl]-4-Ylsulfonamido)-3-Methylbutanoic Acid (S)-2-(4’-溴-[1,1’-联苯]-4-基磺酰胺基)-3-甲基丁酸
CAS 199850-67-4 MFCD09038565
化学结构图
SMILES: CC(C)[C@H](NS(=O)(=O)C1=CC=C(C=C1)C1=CC=C(Br)C=C1)C(O)=O
化学属性
| Mol. Formula | C17H18BrNO4S |
|---|---|
| Mol. Weight | 412.302 |
别名和识别编码
| Chemical Name | (S)-2-(4’-Bromo-[1,1’-Biphenyl]-4-Ylsulfonamido)-3-Methylbutanoic Acid |
|---|---|
| Chemical Name Translation | (S)-2-(4’-溴-[1,1’-联苯]-4-基磺酰胺基)-3-甲基丁酸 |
信息真实价格透明
资金保障
专业采购外包团队在线服务
信息真实价格透明
资金保障
专业采购外包团队在线服务
品牌质保精细包装
现货库存
一流品牌服务
相关文献及参考
- [2]. Kaludercic N, et, al. Inhibiting metalloproteases with PD 166793 in heart failure: impact on cardiac remodeling and beyond. Cardiovasc Ther. Spring 2008;26(1):24-37.
- [3]. Chancey AL, et, al. Effects of matrix metalloproteinase inhibition on ventricular remodeling due to volume overload. Circulation. 2002 Apr 23;105(16):1983-8.
- [1]. O'Brien PM, et, al. Structure-activity relationships and pharmacokinetic analysis for a series of potent, systemically available biphenylsulfonamide matrix metalloproteinase inhibitors. J Med Chem. 2000 Jan 27;43(2):156-66.
- [1]. O'Brien PM, et, al. Structure-activity relationships and pharmacokinetic analysis for a series of potent, systemically available biphenylsulfonamide matrix metalloproteinase inhibitors. J Med Chem. 2000 Jan 27;43(2):156-66.
- [2]. Kaludercic N, et, al. Inhibiting metalloproteases with PD 166793 in heart failure: impact on cardiac remodeling and beyond. Cardiovasc Ther. Spring 2008;26(1):2
